Literature DB >> 16220296

Objective, planimetry-based assessment of megakaryocyte histological pictures in Philadelphia-chromosome-negative chronic myeloproliferative disorders: a perspective for a valuable adjunct diagnostic tool.

Zbigniew Rudzki1, Rafał Kawa, Krzysztof Okoñ, Ewa Szczygieł, Jerzy Stachura.   

Abstract

Philadelphia-chromosome-negative chronic myeloproliferative disorders (Ph- CMPDs)--essential thrombocythemia (ET), chronic idiopathic myelofibrosis (CIMF), and polycythemia vera (PV)--may show clinical and morphological similarities, particularly at the early stages. The differential diagnosis of Ph- CMPDs is important due to their different treatment and prognosis. Cytological features of megakaryocytes are considered valuable in this differentiation. To establish an objective measure of megakaryocyte dysplasia in Ph- CMPDs, we performed computer-assisted morphometry of more than 4,000 cells from 20 cases of ET, 10 of CIMF, 10 of PV, and 10 controls. Megakaryocyte sets from three Ph- CMPDs differed significantly in respect to many planimetric parameters, but not a single shape or size parameter could have been used as a discriminative tool between the entities. However, the discriminant function analysis with the simultaneous assessment of 12 planimetric variables allowed for a proper classification of 20 of 20 ET, 10 of 10 PV, and 9 of 10 CIMF cases based solely on the morphometric features of megakaryocytes. Additionally, we identified certain new patterns of megakaryocytes specific for ET, PV, and CIMF, which, although not dominating in one Ph- CMPD, are unlikely to occur in two others. Objective measurements of megakaryocyte sizes and shapes may assist the diagnosis of Ph- CMPDs.

Entities:  

Mesh:

Year:  2005        PMID: 16220296     DOI: 10.1007/s00428-005-0077-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  26 in total

1.  Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies.

Authors:  J Thiele; H M Kvasnicka; V Diehl; R Fischer; J Michiels
Journal:  Leuk Lymphoma       Date:  1999-04

2.  Deciding on transplantation for myelofibrosis: setting the record straight.

Authors:  Ayalew Tefferi; H Joachim Deeg
Journal:  Mayo Clin Proc       Date:  2004-07       Impact factor: 7.616

3.  Should a platelet limit of 600 x 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages.

Authors:  E Lengfelder; A Hochhaus; U Kronawitter; D Höche; W Queisser; M Jahn-Eder; R Burkhardt; A Reiter; H Ansari; R Hehlmann
Journal:  Br J Haematol       Date:  1998-01       Impact factor: 6.998

Review 4.  Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia.

Authors:  J Laszlo
Journal:  Semin Hematol       Date:  1975-10       Impact factor: 3.851

5.  Chronic myeloproliferative disorders in bone marrow biopsies.

Authors:  A Georgii; K F Vykoupil; T Buhr; H Choritz; U Döhler; V Kaloutsi; M Werner
Journal:  Pathol Res Pract       Date:  1990-02       Impact factor: 3.250

Review 6.  Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.

Authors:  S Murphy; P Peterson; H Iland; J Laszlo
Journal:  Semin Hematol       Date:  1997-01       Impact factor: 3.851

Review 7.  Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification.

Authors:  J Thiele; H M Kvasnicka; R Fischer
Journal:  Ann Hematol       Date:  1999-11       Impact factor: 3.673

8.  Histomorphometric study of megakaryocytes in bone marrow in selected myeloproliferative and lymphoproliferative diseases.

Authors:  Dorota Lemancewicz; Janusz Dziecioł; Janusz Kłoczko; Elzbieta Litwiejko-Pietryńczak; Wanda Bogusłowicz
Journal:  Folia Morphol (Warsz)       Date:  2003-02       Impact factor: 1.183

9.  Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.

Authors:  J Thiele; H M Kvasnicka
Journal:  Ann Hematol       Date:  2003-02-22       Impact factor: 3.673

Review 10.  Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).

Authors:  Jan Jacques Michiels; Juergen Thiele
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.